Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.
about
The use and misuse of positron emission tomography in lung cancer evaluationAssessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm.Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.Functional imaging in lung cancerMeasuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP.An analysis of the utility of handheld PET probes for the intraoperative localization of malignant tissue.Pulmonary imaging using respiratory motion compensated simultaneous PET/MRMolecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapyMetabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer.(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.Associations between the standardized uptake value of (18)F-FDG PET/CT and demographic, clinical, pathological, radiological factors in lung cancer.Positron emission tomography: clinical applications in oncology. Part 1.Advances in positron emission tomographic imaging of lung cancerPositron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma.Quantitative Imaging in Cancer Clinical TrialsPositron emission tomography imaging as a cancer biomarker.Predictive and prognostic value of FDG-PET.Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics.Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scanLung cancer: Morphological and functional approach to screening, staging and treatment planning.PET and PET-CT in radiation treatment planning for lung cancer.PET/CT in therapy evaluation of patients with lung cancer.PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.The role of PET/CT as a prognosticator and outcome predictor in lung cancer.Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer.The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasionPrediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantificationPredictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma.PET-Probe: Evaluation of Technical Performance and Clinical Utility of a Handheld High-Energy Gamma Probe in Oncologic Surgery.Voxel clustering for quantifying PET-based treatment response assessment.Accuracy of amplitude-based respiratory gating for PET/CT in irregular respirations.FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.FDG uptake at the bronchial stump after curative lobectomy for non-small cell lung cancer.Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.Diagnosis of lymph node metastasis by endobronchial ultrasound-guided transbronchial needle aspiration more than 1 year after lung cancer resection: report of a case.VEGF-A and its isoform VEGF₁₂₁ mRNA expression measured by quantitative real-time RT-PCR: correlation with F-18 FDG uptake and aggressiveness of lung adenocarcinoma: preliminary study.
P2860
Q27021838-7487842F-1DB9-4683-B9C1-FD6BB6666202Q35031831-092E2A23-3478-412A-856C-814FB6B067D9Q35216037-F315355F-3B3F-44D9-AB9D-9144BCFF2273Q35402102-55083FB1-2085-4B82-B84C-195A223DD626Q35550676-7C25518A-8BE9-44BC-9E31-FB6384C878E8Q35582969-BFFF4982-341D-437A-B1E5-24B99EED1027Q35744447-87BCF227-AD77-428C-BEA8-F16CC46ED85DQ35761852-08924B26-F67A-4A71-9606-A223A27F7BF0Q35793157-2F41446B-3D1C-4158-8657-1590446F3A9DQ36024114-C7C2E9B9-21C4-4018-83F0-4E35CAAC997AQ36285994-E1F17A34-A065-4A9F-9E8A-12206B2DB8B0Q36317680-7AE51FFC-2A2F-46A9-8AC9-EBC3863920A0Q36334917-B63252EF-E55B-4B7C-927D-59C31DD7DB59Q36341240-EBB1F4D8-F693-428F-B21A-618CFAAE23CAQ36439506-9B63E037-BB14-46E0-8F72-C6B6352FA378Q36477059-96CBEE8C-41C0-4659-A6CF-1662DA4C28F0Q36950458-FA2F2A31-4662-48D7-914A-F32390A0D257Q37129057-B765DAC8-8D1E-4D0E-95AA-58B40C52A9BCQ37404658-475B011B-56EF-4B9F-93D0-B3076A523AEBQ37594999-64E497CB-59AD-4179-A1AF-51027514F75CQ37707376-C5083BB3-5113-47A5-B8EB-1A1DB5015A33Q37732292-BD63D4A9-7299-4B6E-BDA4-4FD46AFDA0E0Q38202189-00910D50-8A51-4E0D-833F-35C439B7888AQ38213643-B63D57E2-2A64-458F-B482-E15B058D49C3Q38234978-980314EE-86E1-48DB-8810-3C5C7F9C7DFFQ38715401-B8F48852-18F2-496C-971A-F6A114C575C6Q39713470-B1D3E7F6-3AB7-4A7E-B6C4-5FE50C449066Q42254342-9BECAFE6-3CA4-4BE5-B7C4-BEBF3CA74605Q42664426-06677565-4030-4EBC-BE79-FEAD6FD66D5FQ43605684-B959341F-C53E-42EB-96C3-F06F233EF413Q43853073-E6BCDDB9-1A92-4994-B3C8-BEB062C07EBEQ46859388-44C16DDF-7BC0-421B-897C-C191B52C696AQ50920033-B80BC368-E6AD-41E8-A1E6-6571B693D8C0Q51715542-FE872301-2A16-4449-B515-863C33F4FCA8Q52987662-B30D1CB8-C96A-413D-8585-48A0636D6C5DQ52989702-4A0733C8-825F-4E9A-96F3-C8BB50EF9D68Q53063682-61810C7E-D3CE-46F9-8E7F-C604C85E6B8EQ53161184-1EE1D23B-E1E2-4608-B297-ABE75BBF6ECCQ53214260-70490638-DD73-4F6D-B98D-560AFF3A8FC8Q53266845-F60C40AD-2A65-437B-A8F8-2238029A7940
P2860
Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Positron-emission tomography i ...... ung cancer: systematic review.
@ast
Positron-emission tomography i ...... ung cancer: systematic review.
@en
type
label
Positron-emission tomography i ...... ung cancer: systematic review.
@ast
Positron-emission tomography i ...... ung cancer: systematic review.
@en
prefLabel
Positron-emission tomography i ...... ung cancer: systematic review.
@ast
Positron-emission tomography i ...... ung cancer: systematic review.
@en
P1433
P1476
Positron-emission tomography i ...... lung cancer: systematic review
@en
P2093
Christophe Dooms
Johan Vansteenkiste
P304
P356
10.1016/S1470-2045(04)01564-5
P577
2004-09-01T00:00:00Z